NCT03952572
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma
Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma
Peking University·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Peripheral T-cell Lymphoma
- Drug/Device/Intervention
- Cyclophosphamide
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Peking University
- Location
- Beijing, China
Timeline & enrollment
- Phase
- Phase 3
- Start date
- May 10, 2019
- End date
- Apr 30, 2023
- Enrollment
- 244 participants
Primary outcome
Response rate
Summary
Primary objective of the study is to compare the efficacy and safety of CDOP versus CHOP for
 newly diagnosed peripheral T-cell lymphoma (PTCL).
ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03952572
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT03952572 through Pure Global AI's free database. This Phase 3 trial is sponsored by Peking University and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 244 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.